Losses were up in 2007 for Ondine Biopharma Corp. (TSX:OBP): $13.2 million compared with $12 million the year before.
The Vancouver company said sales of its Periowave laser technology, which is used to treat gum disease, were flat at $1.6 million.
Ondine added that increased general, administration, marketing and sales costs contributed to the higher loss.
The biotechnology company develops non-antibiotic and anti-infective remedies for bacterial, viral and fungal infections.
Ondine's share price range during the past week: between $0.90 and $0.95; 52-week high: $1.84; 52-week low: $0.65.